KRAS and familial pancreatic carcinoma: Although we did not stratify HIT101481851s efficacy by such molecular markers, its mechanism of action suggests it may be especially efficacious in KRAS/p53-mutant PDAC, which accounts for over 60% of pancreatic cancers.